Arbutus Biopharma Corporation (ABUS) News

Arbutus Biopharma Corporation (ABUS): $2.60

0.11 (+4.42%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add ABUS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#145 of 363

in industry

Filter ABUS News Items

ABUS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ABUS News From Around the Web

Below are the latest news stories about ARBUTUS BIOPHARMA CORP that investors may wish to consider to help them evaluate ABUS as an investment opportunity.

Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD

Initial data from the combination of imdusiran and VTP-300 show meaningful reductions of HBsAg levels that were maintained well below baseline.In HBV003, 31% of participants with screening HBsAg level of ≤200 IU/mL had >1 log HBsAg reductions. VTP-300 was generally well-tolerated in both trials. OXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced the presentation of data from two HBV clinical trials at Th

Yahoo | November 9, 2023

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline Preliminary data in subset of patients given imdusiran and then VTP-300 show early signs of immune activation WARMINSTER, Pa. and OXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatiti

Yahoo | November 9, 2023

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2023 Earnings Call Transcript

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2023 Earnings Call Transcript November 7, 2023 Arbutus Biopharma Corporation reports earnings inline with expectations. Reported EPS is $-0.12 EPS, expectations were $-0.12. Operator: Good day, and thank you for standing by. Welcome to the Arbutus Third Quarter Corporate and Financial Update Conference Call. [Operator Instructions] Please be advised that […]

Yahoo | November 9, 2023

Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week

Celebrations may be in order for Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders, with the analysts...

Yahoo | November 9, 2023

Arbutus to Present at Jefferies London Healthcare Conference

WARMINSTER, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following investor conference: Jefferies London Healthcare Conference: Formal presentation on Wednesday,

Yahoo | November 8, 2023

Q3 2023 Arbutus Biopharma Corp Earnings Call

Q3 2023 Arbutus Biopharma Corp Earnings Call

Yahoo | November 8, 2023

Arbutus Biopharma Corp (ABUS) Reports Q3 2023 Financial Results

Company continues clinical trials and reduces workforce by 24% amidst pipeline optimization

Yahoo | November 7, 2023

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Multiple data presentations upcoming at AASLD – The Liver Meeting®, including preliminary data from Phase 2a clinical trial combining imdusiran, our RNAi therapeutic, with VTP-300, an HBV antigen-specific immunotherapy Dosing continues in two Phase 2a combination clinical trials with imdusiran and in a Phase 1a/1b clinical trial with AB-101, our oral PD-L1 checkpoint inhibitor Reducing workforce by 24% as a result of recent pipeline optimization Cash runway extended into first quarter 2026 Confe

Yahoo | November 7, 2023

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Michael J. McElhaugh, Arbutus Co-founder and COO, to Serve as Interim CEO WARMINSTER, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis B virus (cHBV) infection, today announced that William Collier will retire from his position as the Company’s President and Chief Executive Officer, and as a mem

Yahoo | November 7, 2023

12 Best Micro Cap Stocks To Invest In

In this piece, we will take a look at the 12 best micro cap stocks to invest in. To skip our introduction to micro cap investing, some benefits, and potential risks, you can skip ahead to 5 Best Micro Cap Stocks To Invest In. Depending on who you ask, it can be argued that the […]

Yahoo | October 30, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!